Solvay Pharmaceuticals' Creon (pancrealipase delayed-release) has received US FDA approval for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Solvay Pharmaceuticals' Creon (pancrealipase delayed-release) has received US FDA approval for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Creon is the first pancreatic enzyme product (PEP) approved under an FDA initiative aimed at getting unapproved PEPs off the...
Already approved in two rare obesity conditions, Rhythm’s Imcivree looks on course to gain acquired hypothalamic obesity approval and reach blockbuster status.
Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
